i
The Potential Economic Value of a “Universal” (Multi-Year) Influenza Vaccine
-
Sep 21 2011
Source: Influenza Other Respi Viruses. 6(3):167-175. -
Alternative Title:Influenza Other Respi Viruses
-
Personal Author:
-
Description:Background
Limitations of the current annual influenza vaccine have led to ongoing efforts to develop a “universal” influenza vaccine, i.e., one that targets a ubiquitous portion of the influenza virus so that the coverage of a single vaccination can persist for multiple years.
Objectives
To estimate the economic value of a “universal” influenza vaccine compared to the standard annual influenza vaccine, starting vaccination in the pediatric population (2–18 year olds), over the course of their lifetime.
Patient/methods
Monte Carlo decision analytic computer simulation model
Results
Universal vaccine dominates (i.e., less costly and more effective) the annual vaccine when the universal vaccine cost ≤$100/dose and efficacy ≥75% for both the 5 and 10 year duration. The universal vaccine is also dominant when efficacy is ≥50% and protects for 10 years. A $200 universal vaccine was only cost-effective when ≥75% efficacious for a 5 year duration when annual compliance was 25% and for a 10 year duration for all annual compliance rates. A universal vaccine is not cost-effective when it cost $200 and when its efficacy is ≤50%. The cost-effectiveness of the universal vaccine increases with the duration of protection.
Conclusions
Although development of a universal vaccine requires surmounting scientific hurdles, our results delineate the circumstances under which such a vaccine would be a cost-effective alternative to the annual influenza vaccine.
-
Subjects:
-
Pubmed ID:21933357
-
Pubmed Central ID:PMC3253949
-
Document Type:
-
Funding:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type:
[PDF-469.10 KB]
Details:
Supporting Files
More +
Email
CDC-INFO
